{
    "nct_id": "NCT03656718",
    "official_title": "Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy",
    "inclusion_criteria": "* Histologic or cytologic confirmation of advanced (metastatic and/or unresectable) solid tumors of one of the following tumor types:\n\n  1. Metastatic squamous or non-squamous NSCLC\n  2. RCC, advanced or metastatic\n  3. Melanoma\n  4. HCC\n  5. CRC, metastatic (MSI-H or dMMR)\n  6. In Part B, other solid tumor types may be considered at the discretion of the Medical Monitor\n  7. In Part E, Metastatic urothelial carcinoma\n* Measurable disease as per RECIST version 1.1 criteria\n* ECOG performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain metastases or leptomeningeal metastases\n* Ocular melanoma\n* Active, known, or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}